课题基金 / 基金详情

项目摘要

项目成果

Michael R. Farzan的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 冠状病毒,包括SARS-CoV-2,对公众健康构成明显和迫在眉睫的威胁。这 CAMPP计划开发针对多种冠状病毒蛋白和复制的化合物 流程。这些蛋白质包括公认的药物靶点,如蛋白酶(项目1)和 复制(项目2),以及较高风险目标(项目4)。项目3--瞄准可吸毒人群 冠状病毒蛋白专注于四个不太成熟的病毒过程,尽管如此, 至少在一个证明原则的例子中成功地瞄准了目标。其中包括冠状病毒解旋酶。 NSP13(目标1,由Scripps Research的Sumit Chandra领导),核衣壳(N)蛋白,它包装 RNA基因组并与萌发中的病毒粒子有关(Aim 2,由Suganya Selvarajah在Prosetta领导), 编码其活性可能有助于病毒粒子组装的离子通道的E蛋白(目标3, 由加州大学圣迭戈分校的John Guatelli领导)和Spike(S)蛋白介导病毒和细胞的融合 膜(目标4,由佛罗里达州斯克里普斯的迈克尔·法赞领导)。这四个目标提供了四个平行的 “射门得分”。在每一种情况下,牵头实验室都确定了新的原则证明化学物质。 抑制每种蛋白质的活性。这些化合物是通过公共管道开发的,并且 同时,每个目标都追求定制的高通量屏幕,旨在应对独特的挑战 每一个目标。在提案的最后几年,发展资源被分配给 前景看好的化合物。因此,这项提案的总体结构旨在最大限度地增加 开发一种有效的抑制或冠状病毒复制。
英文摘要
SUMMARY Coronaviruses, including SARS-CoV-2, pose obvious and imminent dangers to public health. This CAMPP proposal develops compounds that target multiple coronaviruses proteins and replication processes. These proteins include well established drug targets such as protease (Project 1) and replicase (Project 2), and as well as higher risk targets (Project 4). Project 3 – Targeting Druggable Coronavirus Proteins focuses on four less established viral processes that nonetheless have been successfully targeted in at least one proof-of-principle example. These include the coronaviral helicase nsp13 (Aim 1, led by Sumit Chandra at Scripps Research), the nucleocapsid (N) protein, which packages the RNA genome and associates with the budding virion (Aim 2, led by Suganya Selvarajah at Prosetta), the E protein, which encodes an ion channel whose activity likely contributes to virion assembly (Aim 3, led by John Guatelli from UCSD), and the spike (S) protein with mediates fusion of the viral and cellular membranes (Aim 4, lead by Michael Farzan at Scripps Florida). These four targets afford four parallel “shots on goal”. In each case, the lead laboratory has identified novel proof-of-principle chemical matter inhibiting the activity of each protein. These compounds are developed through a common pipeline, and in parallel each aim pursues a custom high-throughput screen designed to address the challenges unique to each target. In the later years of the proposal developmental resources are allocated to the most promising compounds. The overall structure of this proposal is thus designed to maximize the chance of developing an effective inhibitor or coronavirus replication.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
eCD4-mediated control of SIV infection in the brain
  • 批准号:
    10698442
  • 项目类别:
  • 资助金额:
    $91.41万
  • 财政年份:
    2023
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Safe, CRISPR/Cas-free B cell editing for therapeutic applications
  • 批准号:
    10725412
  • 项目类别:
  • 资助金额:
    $22.13万
  • 财政年份:
    2023
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
  • 批准号:
    10573644
  • 项目类别:
  • 资助金额:
    $8.28万
  • 财政年份:
    2022
  • 负责人:
    Michael R. Farzan
  • 依托单位:
Improving mRNA vaccines with extracellular vesicle-associated immunogens
  • 批准号:
    10850617
  • 项目类别:
  • 资助金额:
    $18.96万
  • 财政年份:
    2022
  • 负责人:
    Michael R. Farzan
  • 依托单位:
海外基金